# Identification of high-performing antibodies for Rab1A and Rab1B for use in Western Blot, immunoprecipitation and immunofluorescence

**Authors:** Vera Ruíz Moleón, Maryam Fotouhi, Riham Ayoubi, Sara González Bolívar, Kathleen Southern, Peter S. McPherson, Carl Laflamme

PMC · DOI: 10.12688/f1000research.143928.1 · 2023-12-11

## TL;DR

This study identifies reliable antibodies for Rab1A and Rab1B to improve research reproducibility in studying these proteins involved in disease.

## Contribution

The study provides validated, high-performing antibodies for Rab1A and Rab1B using standardized protocols and knockout cell comparisons.

## Key findings

- Seven high-quality Rab1A antibodies and five Rab1B antibodies were validated for Western Blot, immunoprecipitation, and immunofluorescence.
- Antibody performance was assessed using knockout cell lines and isogenic controls to ensure specificity.
- The results are part of a larger initiative to improve antibody reproducibility in human protein research.

## Abstract

Rab1 is a highly conserved small GTPase that exists in humans as two isoforms: Rab1A and Rab1B, sharing 92% sequence identity. These proteins regulate vesicle trafficking between the endoplasmic reticulum (ER) and Golgi and within the Golgi stacks. Rab1A and Rab1B may be oncogenes, as they are frequently dysregulated in various human cancers. Moreover, they contribute to the progression of Parkinson’s disease. The availability of high-quality antibodies specific for Rab1A or Rab1B is essential to understand the distinct functions of these Rab1 proteins in both health and diseaseand to enhance the reproducibility of research involving these proteins. In this study, we characterized seven antibodies targeting Rab1A and five antibodies targeting Rab1B for Western Blot, immunoprecipitation, and immunofluorescence using a standardized experimental protocol based on comparing read-outs in knockout cell lines and isogenic parental controls. These studies are part of a much larger, collaborative initiative seeking to address the antibody reproducibility issue by characterizing commercially available antibodies for human proteins and publishing the results openly as a valuable resource for the scientific community. While uses of antibodies and protocols vary between laboratories, we encourage readers to use this report as a guide to select the most appropriate antibodies for their specific needs.

## Linked entities

- **Genes:** RAB1A (RAB1A, member RAS oncogene family) [NCBI Gene 5861], RAB1B (RAB1B, member RAS oncogene family) [NCBI Gene 81876]
- **Proteins:** RAB1A (RAB1A, member RAS oncogene family), RAB1B (RAB1B, member RAS oncogene family)
- **Diseases:** Parkinson’s disease (MONDO:0005180), cancer (MONDO:0004992)

## Full-text entities

- **Genes:** RAB1A (RAB1A, member RAS oncogene family) [NCBI Gene 5861] {aka RAB1, YPT1}, RAB1B (RAB1B, member RAS oncogene family) [NCBI Gene 81876]
- **Diseases:** Parkinson's disease (MESH:D010300), cancers (MESH:D009369)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC10979127/full.md

---
Source: https://tomesphere.com/paper/PMC10979127